Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nela Klein González"'
Autor:
Lorenza Pérez Amill, Mercedes Armand Ugon, Sergio Peña Pérez, Maria Val Casals, Claudio Santos, Gerard Frigola, José Ramon Álamo, Francesca Guijarro, Alfredo Minguela, Àlex Bataller, Juan Gonzalo Correa Saldarriaga, Berta Casanovas Albertí, Mireia Uribe Herranz, Europa Azucena Gonzalez, Daniel Benitez-Ribas, Diego Sanchez, Nestor Tirado, Paola Romecin, Talía Velasco, Pablo Menendez, Antonio Martínez, Montserrat Rovira Tarrats, Jordi Esteve, Avaro Urbano Ispizua, Julio Delgado, Manel Juan, Nela Klein González
Publikováno v:
HemaSphere, Vol 7, p e29611a0 (2023)
Externí odkaz:
https://doaj.org/article/071fe08eee104e288eb493ce7a142c4c
Autor:
Lorena Pérez-Amill, Mercedes Armand-Ugon, Sergio Peña, Maria Val Casals, Claudio Santos, Gerard Frigola, Alfredo Minguela, Àlex Bataller Torralba, Berta Casanovas, José Álamo, Mireia Uribe, Diego Sánchez-Martínez, Néstor Tirado, Clara Bueno, Paola Alejandra Romecín, Pablo Menéndez, Antonio Martínez, Montserrat Rovira, Jordi Esteve, Álvaro Urbano-Ispizua, Julio Delgado, Manel Juan, Nela Klein-González
Publikováno v:
Blood. 140:7379-7381
Autor:
Mireia Uribe-Herranz, Nela Klein-González, Luis Gerardo Rodríguez-Lobato, Manel Juan, Carlos Fernández de Larrea
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 3, p 1026 (2021)
Hematological malignancies, including multiple myeloma, lymphoma, and leukemia, are a heterogeneous group of neoplasms that affect the blood, bone marrow, and lymph nodes. They originate from uncontrolled growth of hematopoietic and lymphoid cells fr
Externí odkaz:
https://doaj.org/article/afb2e0126ef8447580697bd8498b740f
Autor:
Miquel Lozano, Iolanda Jordan, Enric Garcia-Rey, Manel Juan, Miguel Caballero-Baños, Laia Guardia, Pedro Castro, E. Azucena González, Andrea Scalise, Eva Giné, Jordi Esteve, Ferran Torres, Neus Villamor, Esteve Trias, Alvaro Urbano-Ispizua, Marina Díaz-Beyá, Julio Delgado, Cristina Llanos, Sara Fernández, Unai Perpiñá, Josep M. Canals, Marta Español-Rego, Montserrat Torrebadell, Federico Ramos, Sara Varea, Mercedes Montoro, Tycho Baumann, Joan Cid, Anna Alonso-Saladrigues, M. Castella, Joaquín Sáez-Peñataro, Gonzalo Calvo, Valentín Ortiz-Maldonado, Susana Rives, Daniel Benitez-Ribas, Laia Alsina, Albert Català, Anna Faura, Nela Klein-González, Guillermo Suñe
Publikováno v:
Molecular Therapy. 29:636-644
We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells targeting CD19) in adult and pediatric patients with relapsed/refractory CD19+ malignancies. Patients received cyclophosphamide and fludarabine followed by ARI-0001
Autor:
Carlos Fernández de Larrea, Mireia Uribe-Herranz, Luis Gerardo Rodríguez-Lobato, Manel Juan, Nela Klein-González
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 1026, p 1026 (2021)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
Hematological malignancies, including multiple myeloma, lymphoma, and leukemia, are a heterogeneous group of neoplasms that affect the blood, bone marrow, and lymph nodes. They originate from uncontrolled growth of hematopoietic and lymphoid cells fr
Autor:
A Bartoló-Ibars, Manel Juan, Europa Azucena González-Navarro, Julio Delgado, D Benítez, M Español, Montserrat Torrebadell, Eva Giné, Nela Klein-González, Miguel Caballero-Baños, Tycho Baumann, M. Castella, Jordi Yagüe, Alvaro Urbano-Ispizua, Susana Rives, Valentín Ortiz-Maldonado, R Cabezón, Pedro Castro, Jordi Esteve
Publikováno v:
E-Poster Presentations.
Background Chimeric Antigen Receptor (CAR)-T cells directed against CD19 have induced high rates of response in patients with relapsed/refractory (R/R) B-cell malignancies. Two CD19-targeting constructs have been approved by the FDA and EMA (Yescarta
Autor:
Valentín, Ortíz-Maldonado, Susana, Rives, Maria, Castellà, Anna, Alonso-Saladrigues, Daniel, Benítez-Ribas, Miguel, Caballero-Baños, Tycho, Baumann, Joan, Cid, Enric, Garcia-Rey, Cristina, Llanos, Montserrat, Torrebadell, Neus, Villamor, Eva, Giné, Marina, Díaz-Beyá, Laia, Guardia, Mercedes, Montoro, Albert, Català, Anna, Faura, E Azucena, González, Marta, Español-Rego, Nela, Klein-González, Laia, Alsina, Pedro, Castro, Iolanda, Jordan, Sara, Fernández, Federico, Ramos, Guillermo, Suñé, Unai, Perpiñá, Josep M, Canals, Miquel, Lozano, Esteve, Trias, Andrea, Scalise, Sara, Varea, Joaquín, Sáez-Peñataro, Ferran, Torres, Gonzalo, Calvo, Jordi, Esteve, Álvaro, Urbano-Ispizua, Manel, Juan, Julio, Delgado
Publikováno v:
Mol Ther
We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells targeting CD19) in adult and pediatric patients with relapsed/refractory CD19(+) malignancies. Patients received cyclophosphamide and fludarabine followed by ARI-000
Autor:
Andreas Draube, Nela Klein-González, Stefanie Mattheus, Corinne Brillant, Martin Hellmich, Andreas Engert, Michael von Bergwelt-Baildon
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e18801 (2011)
BACKGROUND: More than 200 clinical trials have been performed using dendritic cells (DC) as cellular adjuvants in cancer. Yet the key question whether there is a link between immune and clinical response remains unanswered. Prostate and renal cell ca
Externí odkaz:
https://doaj.org/article/0fa4f8f0473d4edc89a45e3ecd975a38
Autor:
Kirsten A. Fairfax, Michael von Bergwelt-Baildon, Udo Holtick, Nela Klein-González, Martin R Weihrauch
Evaluation of: Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a Phase I/II study. J. Clin. Oncol. 28(28), 4324-4332 (2010). Despite high response rates of the follicular B-cell lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa72e72fc52902ed9f7419e56e12e268
https://www.ncbi.nlm.nih.gov/pubmed/21434797
https://www.ncbi.nlm.nih.gov/pubmed/21434797
Autor:
Lorena Pérez-Amill, Àlex Bataller, Julio Delgado, Jordi Esteve, Manel Juan, Nela Klein-González
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Chimeric antigen receptor (CAR) T therapies are being developed for acute myeloid leukemia (AML) on the basis of the results obtained for other haematological malignancies and the need of new treatments for relapsed and refractory AML. The biggest ch
Externí odkaz:
https://doaj.org/article/9f65a8786ec24b6c85cf0f87016b7bfe